Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 9/20 | 0.57 |
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | BRD1 | O95696 | 2/20 | 0.43 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119743 | 0.88 | BRPF1 (0.52) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL763370 | 0.84 | BRPF1 (0.59) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL9320188 | 0.83 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL9411117 | 0.83 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL13886419 | 0.81 | BRPF1 (0.56) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL17979340 | 0.81 | BRPF1 (0.37) | BRPF1ALOX5KCNA5 | |
| SCHEMBL14518794 | 0.80 | BRPF1 (0.54) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL9124674 | 0.80 | ALOX5 (0.42) | BRPF1ALOX5KCNA5 | |
| SCHEMBL9121051 | 0.78 | SCN7A (0.36) | BRPF1ALOX5 | |
| SCHEMBL13886461 | 0.78 | BRPF1 (0.51) | BRPF1BRD4BRD9CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED | 2002-04-04 | — | — | US | disclosed |
| US-6251913-B1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0667855-B1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| US-5688822-A | ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIALLERGEN | G.D. SEARLE & CO. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5635514-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS | G. D. SEARLE & COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| US-5616596-A | Substituted arylalkynyl-and heteroarylalkynl-N-hydroxyurea inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1997-04-01 | — | — | US | disclosed |
| US-5196419-A | Lipoxygenase enzyme inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-23 | — | — | US | disclosed |
| EP-0505122-A1 | Alpha, alpha-dialkylbenzyl derivatives | ZENECA LIMITED (GB) | 1992-09-23 | — | — | EP | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| EP-0466452-A2 | Thioxo heterocycles and their pharmaceutical use | ZENECA LIMITED (GB) | 1992-01-15 | — | — | EP | disclosed |
| EP-0462830-A2 | Cyclic ether derivatives | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
| EP-0385679-A2 | Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385663-A2 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385680-A2 | Heterocyclic ethers as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | MMP1, HCAR1, MMP13 | BRPF1 2341/4885BRD4 1676/4885BRD9 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.